If this is still relevant (http://www.graceforrett.com/rett-syndrome/r168x/nnz-2566-in-plain-english/) then it seems testing nnz-2566 on adults is a precursor to then testing it in the pediatric population. The article was written by Steve Kaminsky and Nancy Jones.
That would suggest that a successful result here sets up a similar trial for younger patients, and perhaps a wider Phase 3 trial focussed on efficacy? But I'm really shooting in the dark with this.
In terms of applications for Orphan and Breakthrough status for Rett, that will inevitably happen for 2566 if efficacy comes through.
The Glypromate failure, page-15
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |